However, the combination of all three therapies (anti-PD1 plus anti-CTLA4 plus Prexasertib) or “PPC” was synergistic and significantly improved survival with 80% of the mice tumor-free at the end of the study (p<0.01) (Fig. 3G). Here, CTLA4 is linked to neoplasm.